Ivy N Haskins1,2, Ricard Corcelles3, Dvir Froylich3, Mena Boules3, Amani Hag3, Bartolome Burguera4, Phillip R Schauer3, Matthew Kroh3, Stacy A Brethauer3. 1. Bariatric and Metabolic Institution, Cleveland Clinic Foundation, Cleveland, OH, USA. haskini@ccf.org. 2. Clinical Research Fellow, Cleveland Clinic Foundation, 9500 Euclid Avenue, A100, Cleveland, OH, 44195, USA. haskini@ccf.org. 3. Bariatric and Metabolic Institution, Cleveland Clinic Foundation, Cleveland, OH, USA. 4. Department of Endocrinology, Diabetes, and Metabolism, Cleveland Clinic Foundation, Cleveland, OH, USA.
Abstract
BACKGROUND: It is well accepted that bariatric surgery has cardiovascular and metabolic effects independent of weight loss. METHODS: Weight loss outcomes of patients undergoing Roux-en-Y gastric bypass (RYGB) at a high volume referral center were collected at 1 year postoperatively. Patients with failed primary weight loss were identified. Primary inadequate weight loss was defined as total body weight loss less than 15 %. Changes in hypertension (HTN), dyslipidemia, type 2 diabetes mellitus (T2DM), and metabolic syndrome profiles were investigated using Student's t test. RESULTS: A total of 2500 patients underwent RYGB from the years 2001-2013 at our institution. One hundred five (4.2 %) patients had primary inadequate weight loss. Within this cohort, 81 (77.1 %) patients had hypertension, 67 (63.8 %) had dyslipidemia, 53 (50.5 %) had type 2 diabetes mellitus, and 66 (62.9 %) patients had metabolic syndrome. At 1 year postoperatively, all metabolic parameters were significantly improved. Measures of metabolic disease included high-density lipoprotein (HDL) (46.3 ± 11.6 versus 54.1 ± 12.7 mg/dL, p < 0.01), low-density lipoprotein (LDL) (103.6 ± 35.8 versus 89.2 ± 30.0 mg/dL, p < 0.01), triglycerides (177.3 ± 139.1 versus 117.6 ± 59.3 mg/dL, p < 0.01), mean plasma glucose (128.9 ± 55.3 versus 102.7 ± 27.3 mg/dL, p < 0.01), and hemoglobin A1C (7.3 ± 1.9 versus 6.1 ± 1.0 %, p < 0.01). HTN was noted to improve in 27 (33.3 %) patients based on a decrease in the number of anti-hypertensives used (1.7 ± 1.0 versus 1.3 ± 1.3, p < 0.01), and 21 (31.8 %) patients had resolution of their metabolic syndrome. CONCLUSION: Improvement in cardiometabolic comorbidities still occurs despite suboptimal weight loss following RYGB.
BACKGROUND: It is well accepted that bariatric surgery has cardiovascular and metabolic effects independent of weight loss. METHODS:Weight loss outcomes of patients undergoing Roux-en-Y gastric bypass (RYGB) at a high volume referral center were collected at 1 year postoperatively. Patients with failed primary weight loss were identified. Primary inadequate weight loss was defined as total body weight loss less than 15 %. Changes in hypertension (HTN), dyslipidemia, type 2 diabetes mellitus (T2DM), and metabolic syndrome profiles were investigated using Student's t test. RESULTS: A total of 2500 patients underwent RYGB from the years 2001-2013 at our institution. One hundred five (4.2 %) patients had primary inadequate weight loss. Within this cohort, 81 (77.1 %) patients had hypertension, 67 (63.8 %) had dyslipidemia, 53 (50.5 %) had type 2 diabetes mellitus, and 66 (62.9 %) patients had metabolic syndrome. At 1 year postoperatively, all metabolic parameters were significantly improved. Measures of metabolic disease included high-density lipoprotein (HDL) (46.3 ± 11.6 versus 54.1 ± 12.7 mg/dL, p < 0.01), low-density lipoprotein (LDL) (103.6 ± 35.8 versus 89.2 ± 30.0 mg/dL, p < 0.01), triglycerides (177.3 ± 139.1 versus 117.6 ± 59.3 mg/dL, p < 0.01), mean plasma glucose (128.9 ± 55.3 versus 102.7 ± 27.3 mg/dL, p < 0.01), and hemoglobin A1C (7.3 ± 1.9 versus 6.1 ± 1.0 %, p < 0.01). HTN was noted to improve in 27 (33.3 %) patients based on a decrease in the number of anti-hypertensives used (1.7 ± 1.0 versus 1.3 ± 1.3, p < 0.01), and 21 (31.8 %) patients had resolution of their metabolic syndrome. CONCLUSION: Improvement in cardiometabolic comorbidities still occurs despite suboptimal weight loss following RYGB.
Entities:
Keywords:
Diabetes mellitus; Gastric bypass; Metabolic outcomes; Obesity; Weight loss
Authors: M S Hickey; W J Pories; K G MacDonald; K A Cory; G L Dohm; M S Swanson; R G Israel; H A Barakat; R V Considine; J F Caro; J A Houmard Journal: Ann Surg Date: 1998-05 Impact factor: 12.969
Authors: Eric A Finkelstein; Olga A Khavjou; Hope Thompson; Justin G Trogdon; Liping Pan; Bettylou Sherry; William Dietz Journal: Am J Prev Med Date: 2012-06 Impact factor: 5.043
Authors: Lotta Delling; Kristjan Karason; Torsten Olbers; David Sjöström; Björn Wahlstrand; Björn Carlsson; Lena Carlsson; Kristina Narbro; Jan Karlsson; Carl Johan Behre; Lars Sjöström; Kaj Stenlöf Journal: J Obes Date: 2010-08-12
Authors: Francesco Rubino; Michel Gagner; Paolo Gentileschi; Subhash Kini; Shoji Fukuyama; John Feng; Ed Diamond Journal: Ann Surg Date: 2004-08 Impact factor: 12.969
Authors: Ivy N Haskins; Andrew T Strong; Matthew T Allemang; Kalman P Bencsath; John H Rodriguez; Matthew D Kroh Journal: Surg Endosc Date: 2017-07-21 Impact factor: 4.584
Authors: Ivy N Haskins; Tammy Ju; Ashlyn E Whitlock; Lisbi Rivas; Richard L Amdur; Paul P Lin; Khashayar Vaziri Journal: Obes Surg Date: 2018-09 Impact factor: 4.129
Authors: Charlotte M Fries; Sven-Bastiaan Haange; Ulrike Rolle-Kampczyk; Andreas Till; Mathis Lammert; Linda Grasser; Evelyn Medawar; Arne Dietrich; Annette Horstmann; Martin von Bergen; Wiebke K Fenske Journal: Metabolites Date: 2022-05-06